In the BioHarmony Drug Report Database
Valdecoxib
Bextra (valdecoxib) is a small molecule pharmaceutical. Valdecoxib was first approved as Bextra on 2001-11-16. It is used to treat dysmenorrhea, osteoarthritis, and rheumatoid arthritis in the USA. The pharmaceutical is active against prostaglandin G/H synthase 2. In addition, it is known to target carbonic anhydrase 12 and carbonic anhydrase 2.
Trade Name
|
Bextra |
|---|---|
Common Name
|
valdecoxib |
ChEMBL ID
|
CHEMBL865 |
Indication
|
dysmenorrhea, osteoarthritis, rheumatoid arthritis |
Drug Class
|
Cyclooxygenase-2 inhibitors |
Image (chem structure or protein)